| Title |
Targeting 20-HETE producing enzymes in cancer – rationale, pharmacology, and clinical potential
|
|---|---|
| Published in |
OncoTargets and therapy, March 2013
|
| DOI | 10.2147/ott.s31586 |
| Pubmed ID | |
| Authors |
Anna Alexanian, Andrey Sorokin |
| Abstract |
Studies demonstrate that lipid mediator 20-Hydroxyeicosatetraenoic acid (20-HETE) synthesis and signaling are associated with the growth of cancer cells in vitro and in vivo. Stable 20-HETE agonists promote the proliferation of cancer cells, whereas selective inhibitors of the 20-HETE-producing enzymes of the Cytochrome (CYP450)4A and CYP4F families can block the proliferation of glioblastoma, prostate, renal cell carcinoma, and breast cancer cell lines. A recent observation that the expression of CYP4A/4F genes was markedly elevated in thyroid, breast, colon, and ovarian cancer further highlights the significance of 20-HETE-producing enzymes in the progression of different types of human cancer. These findings provide the rationale for targeting 20-HETE-producing enzymes in human cancers and set the basis for the development of novel therapeutic strategies for anticancer treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | 3% |
| Unknown | 36 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 22% |
| Student > Doctoral Student | 6 | 16% |
| Student > Master | 6 | 16% |
| Student > Ph. D. Student | 4 | 11% |
| Student > Bachelor | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 8 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 8 | 22% |
| Biochemistry, Genetics and Molecular Biology | 7 | 19% |
| Medicine and Dentistry | 5 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Chemistry | 2 | 5% |
| Other | 5 | 14% |
| Unknown | 8 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2023.
All research outputs
#8,039,503
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#432
of 2,967 outputs
Outputs of similar age
#64,060
of 206,591 outputs
Outputs of similar age from OncoTargets and therapy
#7
of 22 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,591 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.